In a challenging market environment, TNGX stock has reached a new 52-week low, with shares plummeting to $2.58. According to InvestingPro data, while the company maintains strong liquidity with a ...
Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Tango Therapeutics in a ...
Looking at Tango Therapeutics, Inc.'s ( NASDAQ:TNGX ) insider transactions over the last year, we can see that ...
Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Wednesday, February 5th. Leerink ...
BOSTON—Crystal Adam, President of Research & Development at Tango Therapeutics, Inc. (NASDAQ:TNGX), recently sold a total of ...
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...
(MENAFN- GlobeNewsWire - Nasdaq) BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering ...
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback